您好,欢迎您

【2023 ESMO】抢先看!妇瘤领域口头摘要信息速览

2023年08月21日
编译:肿瘤资讯
来源:肿瘤资讯

2023年ESMO大会将于10月20日-24日在西班牙马德里举行,大会涵盖了肿瘤领域的基础研究、转化研究以及最新的临床研究进展,为临床实践、多学科讨论等提供广阔、卓越的学术平台。

近日,ESMO官方已公布除Late-breaking abstracts(LBA)外的所有口头摘要题目及作者信息。【肿瘤资讯】特别整理本次批露的妇科肿瘤领域重磅研究(主要包含MO:mini oral)标题,以飨读者。

迷你口头报告专场-妇瘤1

本专场有2个LBA摘要待确认(TBC)

摘要号:740MO

Dostarlimab+化疗治疗原发性晚期或复发子宫内膜癌:在ENGOT-EN6-NSGO/GOG-3031/RUBY试验中,按分子分型分析无进展生存期(PFS)和总生存期(OS)结局
 
Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
 
讲者:Mansoor Raza Mirza (Copenhagen, Denmark) 


摘要号:741MO

STRO-002-GM1  I期剂量扩展:Luveltamab Tazevibulin(STRO-002)是一种抗叶酸受体α(FolRα)ADC药物,在复发/进展上皮性子宫内膜癌(EEC)中具有临床活性
 
Luveltamab Tazevibulin (STRO-002), an anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate (ADC), Demonstrates Clinical Activity in Recurrent/Progressive Epithelial Endometrial Cancer (EEC): STRO-002-GM1 Phase 1 Dose Expansion.
 
讲者:Bhavana Pothuri (New York, United States of America)


摘要号:742MO

免疫检查点抑制剂 新辅助治疗 错配修复缺陷型子宫内膜癌
 
Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer.
 
讲者:Marco De Bruyn (Groningen, Netherlands)


摘要号:743MO

QL 1706联合紫杉醇和顺铂/卡铂+/-贝伐珠单抗(Bev)作为1L治疗复发或转移性宫颈癌(r/mCC)的疗效和安全性:一项单臂、多中心II期研究
 
Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): a single-arm, multicenter phase II study.
 
讲者:刘乃富 (Jinan, China)


摘要号:744MO 

AdvanTIG-202:Tislelizumab(TIS)联合或不联合Ociperlimab(OCI)治疗既往接受过治疗的复发/转移性(R/M)宫颈癌(CC)患者的II期随机化、多中心、开放标签研究
 
AdvanTIG-202: Phase 2 Randomized, Multicenter, Open-Label Study of Tislelizumab (TIS) With or Without Ociperlimab (OCI) in Patients (pts) With Previously Treated Recurrent/Metastatic (R/M) Cervical Cancer (CC).
 
讲者:Jung-Yun Lee (Seoul, Korea, Republic of)

迷你口头报告专场-妇瘤2

本专场有3个LBA摘要待确认(TBC)

摘要号:745MO

Raludotatug deruxtecan(R-DXd; DS-6000)单药治疗既往接受过治疗的卵巢癌(OVC)患者:首次人体I期研究的亚组分析
 
Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase 1 study.
 
讲者:Kathleen N. Moore (Oklahoma City, United States of America)


摘要号:746MO 

比较度伐利尤单抗+奥拉帕利+cediranib(DOC)与奥拉帕利+cediranib(OC)或度伐利尤单抗+cediranib(DC)或标准化疗(SOC)治疗既往接受过贝伐珠单抗治疗的铂类耐药卵巢癌的随机II期试验(NRG-GY 023)
 
Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023).
 
讲者:Jung-Min Lee (Bethesda, United States of America)


摘要号:747MO

ENGOT-GYN2/GOG-3051/BOUQUET II期生物标记导向平台研究的初步结果:cobimetinib(cobi)或atezolizumab(atezo)+贝伐珠单抗(bev)用于持续/复发性罕见上皮卵巢癌(eOC)
 
First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed platform study: cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC).
 
讲者:Isabelle L. Ray-Coquard (Lyon, France)



资料来源

https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/calendar


责任编辑:肿瘤资讯-Hedy
排版编辑:肿瘤资讯-Hedy


               
版权声明
本文专供医学专业人士参考,未经著作人许可,不可出版发行。同时,欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明“转自:良医汇-肿瘤医生APP”。